Unique ID issued by UMIN | UMIN000011726 |
---|---|
Receipt number | R000013703 |
Scientific Title | Prospective, randomized, open-label,clinical trial comparing the effects of azilsartan and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases |
Date of disclosure of the study information | 2013/09/15 |
Last modified on | 2020/05/18 14:06:51 |
Prospective, randomized, open-label,clinical trial comparing the effects of azilsartan and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases
Prospective, randomized, open-label,clinical trial comparing the effects of azilsartan and amlodipine
Prospective, randomized, open-label,clinical trial comparing the effects of azilsartan and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases
Prospective, randomized, open-label,clinical trial comparing the effects of azilsartan and amlodipine
Japan |
Hypertension
Cardiology |
Others
NO
Comparison of azilsartan versus amlodipine on blood pressure, endothelial function and levels of markers for inflammation/obesity/oxidative stress/early stage kidney diseases.
Efficacy
Blood pressure (On visit/Home monitoring)
Flow-mediated vasodilation in forearm
Heparin-releasable EC-SOD levels
Eight weeks after administration
Markers indicating obesity (e.g. adiponectin), inflammation (high sensitive CRP), oxidative stress (8-OHdG/ MDA-LDL), early-staged kidney diseases (microalbuminuria)
Eight weeks after administration
Interventional
Cross-over
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Administration of aliskiren
Administration of amlodipine
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Hypertensive patients with no treatment or administration of antihypertensive drug except below drug, who did not reach the recommendation of Hypertension Guidelines issued by Japanese Association of Hypertension 2009
2) Outpatients
3) Subjects who gave written informed consent
1) Allergy against aliskiren/amlodipine
2) Poor-controlled hypertension (DBP>110 mmHg)
3) Poor-controlled diabetes (HbA1c>8.0 %)
4) Secondary hypertension
5) History of stroke, acute coronary syndrome or any cardiovascular diseases needed for inpatient-treatments within 6 months
6) Either level of aspartate aminotransaminase or alanine aminotransferase exceeds three-fold of the normal limits.
7) End stage renal disease
8) Symptomatic (NYHA III or IV) congestive heart failure
9) Malignancies or other diseases with poor prognosis
10) Pregnant
11) Subjects who are taking renin-angiotensin inhibitors
11) Subjects whose doctor in charge do not agree to join the trial
34
1st name | |
Middle name | |
Last name | Katunori Ikewaki |
National Defense Medical College
Department of Internal Medicine
3-2 Namiki, Tokorozawa, Japan
04-2995-1617
katsunorike@ndmc.ac.jp
1st name | |
Middle name | |
Last name | Makoto Ayaori |
National Defense Medical College
Department of Internal Medicine
3-2 Namiki, Tokorozawa, Japan
04-2995-1617
ayaori@ndmc.ac.jp
National Defense Medical College
Foundation for Promotion of Defense Medicine
Non profit foundation
NO
2013 | Year | 09 | Month | 15 | Day |
Unpublished
No longer recruiting
2013 | Year | 09 | Month | 10 | Day |
2013 | Year | 09 | Month | 10 | Day |
2013 | Year | 09 | Month | 15 | Day |
2021 | Year | 03 | Month | 31 | Day |
2013 | Year | 09 | Month | 12 | Day |
2020 | Year | 05 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000013703